Hi. Amols et al., PHYSICIAN PATIENT-DRIVEN RISK ASSIGNMENT IN RADIATION ONCOLOGY - REALITY OR FANCY/, International journal of radiation oncology, biology, physics, 38(3), 1997, pp. 455-461
Citations number
10
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: Treatment plan optimization in radiation oncology entails des
igning multiple x-ray beams to irradiate a tumor to a dose that will a
chieve locoregional control while minimizing normal tissue complicatio
ns, For some anatomical sites, it is possible to estimate tumor contro
l probabilities (TCP) and normal tissue complication probabilities (NT
CP) as a function of radiation dose, Thus, treatment plan optimization
can be based on biologic end points rather than on dose calculations
alone, Given multiple plans with different NTCPs and TCPs, a tradeoff
must be made between maximizing TCP and maintaining an acceptable NTCP
, How do physicians reach these decisions? Can the process be quantifi
ed? Should patients participate in the process? Methods and Materials:
Physicians and patients were asked to rank a series of treatment plan
s having different combinations of TCP and NTCP, Responses were parame
trized into a figure of merit (FM) equation which quantifies predilect
ions of TCP and NTCP. Results: Physician-based FM equations are site-
and patient-specific. Variations exist among physicians, but treatment
plan selection is often conservative in accordance with the primum no
n nocere dictum, FM equations generated from the responses of patients
suggest that some patients may be willing to accept higher treatment
toxicity in exchange for increased TCP. Conclusion: The term ''optimiz
ed treatment plan'' contains inherently subjective criteria which refl
ect one's willingness to accept treatment morbidity in exchange for pr
obability of cure, These criteria may differ among patients and/or phy
sicians, A quantifiable FM may permit the design of custom-made treatm
ent plans that include physician and patient input, (C) 1997 Elsevier
Science Inc.